Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyprien Mbogning

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
BMC Bioinformatics|June 9, 2016
Bagging survival tree procedure for variable selection and prediction in the presence of nonsusceptible patientsCyprien Mbogning, Philippe Broët
Human Heredity|July 24, 2015
A Bagged, Partially Linear, Tree-Based Regression Procedure for Prediction and Variable SelectionCyprien Mbogning, Hervé Perdry, Philippe Broët
Statistics in Medicine|September 1, 2017
A test for comparing current status survival data with crossing hazard functions and its application to immunogenicity of biotherapeuticsSarah Flora Jonas, Cyprien Mbogning, Philippe Broët
Journal of Clinical Bioinformatics|April 18, 2014
A novel tree-based procedure for deciphering the genomic spectrum of clinical disease entitiesCyprien Mbogning, Hervé Perdry, Wilson Toussile, et al.
Plos One|July 1, 2017
A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunologySarah Flora Jonas, Cyprien Mbogning, Signe Hässler, et al.
Plos One|June 14, 2019
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia ADelphine Bachelet, Thilo Albert, Cyprien Mbogning, et al.
JCI Insight|June 8, 2018
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patientsMarsilio Adriani, Petra Nytrova, Cyprien Mbogning, et al.
Plos One|November 3, 2016
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisDelphine Bachelet, Signe Hässler, Cyprien Mbogning, et al.
Seminars in Arthritis and Rheumatism|November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysisJocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
BMC Bioinformatics|June 9, 2016
Bagging survival tree procedure for variable selection and prediction in the presence of nonsusceptible patientsCyprien Mbogning, Philippe Broët
Human Heredity|July 24, 2015
A Bagged, Partially Linear, Tree-Based Regression Procedure for Prediction and Variable SelectionCyprien Mbogning, Hervé Perdry, Philippe Broët
Statistics in Medicine|September 1, 2017
A test for comparing current status survival data with crossing hazard functions and its application to immunogenicity of biotherapeuticsSarah Flora Jonas, Cyprien Mbogning, Philippe Broët
Journal of Clinical Bioinformatics|April 18, 2014
A novel tree-based procedure for deciphering the genomic spectrum of clinical disease entitiesCyprien Mbogning, Hervé Perdry, Wilson Toussile, et al.
Plos One|July 1, 2017
A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunologySarah Flora Jonas, Cyprien Mbogning, Signe Hässler, et al.
Plos One|June 14, 2019
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia ADelphine Bachelet, Thilo Albert, Cyprien Mbogning, et al.
JCI Insight|June 8, 2018
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patientsMarsilio Adriani, Petra Nytrova, Cyprien Mbogning, et al.
Plos One|November 3, 2016
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisDelphine Bachelet, Signe Hässler, Cyprien Mbogning, et al.
Seminars in Arthritis and Rheumatism|November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysisJocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Pageof 1